Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Cocrystal Pharma, Inc. (COCP)

2.71   -0.11 (-3.9%) 01-27 16:00
Open: 2.76 Pre. Close: 2.82
High: 2.88 Low: 2.71
Volume: 58,763 Market Cap: 22(M)

Technical analysis

as of: 2023-01-27 4:43:29 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 3.59     One year: 4.2
Support: Support1: 2.25    Support2: 1.74
Resistance: Resistance1: 3.07    Resistance2: 3.59
Pivot: 2.38
Moving Average: MA(5): 2.73     MA(20): 2.28
MA(100): 2.77     MA(250): 4.38
MACD: MACD(12,26): 0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 78.8     %D(3): 86.5
RSI: RSI(14): 59.6
52-week: High: 7.55  Low: 0.37
Average Vol(K): 3-Month: 50 (K)  10-Days: 97 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ COCP ] has closed below upper band by 22.1%. Bollinger Bands are 11.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.88 - 2.9 2.9 - 2.91
Low: 2.67 - 2.69 2.69 - 2.71
Close: 2.68 - 2.71 2.71 - 2.73

Company Description

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.

Headline News

Thu, 26 Jan 2023
2023-01-26 | NDAQ:COCP | Press Release | Cocrystal Pharma Inc. - Stockhouse

Wed, 25 Jan 2023
Why eHealth Shares Are Trading Higher By Over 18%; Here Are 20 ... - Investing.com UK

Sun, 22 Jan 2023
Cadrenal Therapeutics Stock (NASDAQ:CVKD), Quotes and News ... - Benzinga

Tue, 17 Jan 2023
Influencers spreading sexual health misinformation: Study - RACGP

Fri, 06 Jan 2023
Where Will Cocrystal Pharma Inc (COCP) Stock Go Next After It Is Higher By 14.13% in a Week? - InvestorsObserver

Thu, 17 Nov 2022
Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza A - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 8 (M)
Shares Float 6 (M)
% Held by Insiders 13.1 (%)
% Held by Institutions 20.5 (%)
Shares Short 20 (K)
Shares Short P.Month 13 (K)

Stock Financials

EPS -0.17
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.38
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -16.9
Return on Equity (ttm) -60.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) -1.08
Sales Per Share 0
EBITDA (p.s.) -2.11
Qtrly Earnings Growth 0
Operating Cash Flow -19 (M)
Levered Free Cash Flow -11 (M)

Stock Valuations

PE Ratio -16.43
PEG Ratio 0
Price to Book value 0.5
Price to Sales 0
Price to Cash Flow -1.14

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2018-01-23
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.